Purdue's reformulated OxyContin gets second look by FDA panel
27 August 2009
Sue Sutter
Please Login to read the full article.
27 August 2009
Sue Sutter
sue.sutter@informa.com
The US FDA's outside advisors will take a second look at whether Purdue Pharma's proposed reformulation of OxyContin (oxycodone extended-release) should be approved for sale because it is less likely to be abused or misused.
The anaesthetic and life support drugs and drug safety/risk management...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Janssen wins US FDA nod for chronic pain drug Nucynta ER
- BDSI CEO: Shared fentanyl REMS puts Onsolis on level playing field
- PharmacoFore secures $10M Series B to advance "next generation" abuse resistant opioids, plus propofol alternative
- FDA accepts Endo's harder-to-abuse Opana ER application, with six-month review set
FEATURES
Other Informa Features
EVENTS
26 February 2012
Vancouver Convention Centre | Vancouver, BC, Canada
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
